Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients
Rosemary A. Barnes(Innsbruck Medical University), Johan Maertens(Unknown), Claudie Charbonneau, Monica A. Slavin(The Royal Melbourne Hospital), Cheryl McDade(RTI Health Solutions), Raoul Herbrecht(Institut de Cancérologie Strasbourg), Eric J. Bow(CancerCare Manitoba), Stephanie Earnshaw(RTI International), Haran T. Schlamm(Pfizer (United States)), Michal Kantecki(Pfizer (France)), David Weinstein(Coherus BioSciences (United States)), Orla Morrissey(Alfred Health)
Cited by 27
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k